|
Psoriasis
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Single-nucleotide polymorphisms and haplotypes in the VEGF receptor 3 gene and the haplotype GC in the VEGFA gene are associated with psoriasis in Koreans.
|
18094729 |
2008 |
|
Psoriasis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In the current study, we assessed IL-37 in two well-known psoriasis models: a human keratinocyte cell line (HaCaT) and the keratin 14 VEGF-A-transgenic mouse model.
|
24453242 |
2014 |
|
Psoriasis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests the VEGF +405 C/G polymorphism confers susceptibility to psoriasis in Asians, and that the -460 C/T and -1154 A/G polymorphisms confer susceptibility to psoriasis in Europeans.
|
26600499 |
2015 |
|
Psoriasis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association of the CTG (-2578/-460/+405) haplotype within the vascular endothelial growth factor gene with early-onset psoriasis.
|
18937791 |
2008 |
|
Psoriasis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Haplotype analysis suggests that the coexistence of the polymorphisms rs1799964 (TNF-α), rs2010963 (VEGF), rs833061 (VEGF), and rs6311 (5HT2A) may be a protective factor for psoriasis.
|
31148856 |
2020 |
|
Psoriasis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis.
|
16630077 |
2006 |
|
Psoriasis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, two other VEGF SNPs, rs833061, and rs699947, showed no association with psoriasis susceptibility.
|
28803785 |
2017 |
|
Psoriasis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The allele of rs2237051 G increased the erythema during the treatment, and no polymorphism of VEGF and EGF gene was found to be associated with the susceptibility and efficacy in psoriasis.
|
29843550 |
2018 |
|
Psoriasis
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Single nucleotide polymorphisms of VEGF gene and Psoriasis risk.
|
18054203 |
2008 |
|
Psoriasis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Results from the meta-analysis do support the hypothesis that single-nucleotide polymorphism markers at +405C>G, -460C>T, and -1154G>A of the VEGF gene may serve as biological markers of psoriasis.
|
24678886 |
2014 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our observed genetic interaction between PGF and VEGFA appears relevant to psoriasis, a disease with an angiogenic basis, and may influence development of an antiangiogenic approach to treatment.
|
31545526 |
2020 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
In non-erythrodermic PF, VEGF positivity was similar to HI (P = 0.247), and lower than psoriasis (P = 0.049) and PV (P = 0.049).
|
29489039 |
2018 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
CTD_human |
In future, determination of VEGF gene polymorphisms and thus individual patient VEGF "signatures" may be used as a prognostic factor for psoriasis susceptibility/severity and as a means for optimizing treatment response.
|
16385345 |
2006 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
How relevant are vascular endothelial growth factor and intercellular adhesion molecule in the systemic capillary leak syndrome of psoriasis?
|
29364440 |
2018 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Due to the effect of inhibiting production of VEGF, acitretin can effectively treat psoriasis.
|
31148871 |
2020 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results suggest that alterations in the biology of VEGF may be involved in the pathogenesis of psoriasis.
|
14962110 |
2004 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
LHGDN |
In future, determination of VEGF gene polymorphisms and thus individual patient VEGF "signatures" may be used as a prognostic factor for psoriasis susceptibility/severity and as a means for optimizing treatment response.
|
16385345 |
2006 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The objective of the study was to elucidate the mechanism by which siRNA-mediated silencing of KRT16 affects keratinocyte proliferation and vascular endothelial growth factor (VEGF) secretion in psoriasis through the extracellular signal-related kinase (ERK) signaling pathway.
|
30942529 |
2019 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF), the most critical angiogenic factor, is thought to play important roles during the pathogenesis of psoriasis and may be a promising target for treating psoriasis.
|
25227750 |
2014 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results imply that functional interactions among SP, IL-33, and mast cells leading to VEGF release contribute to inflammatory conditions, such as the psoriasis, a nonallergic hyperproliferative skin inflammatory disorder with a neurogenic component.
|
20160089 |
2010 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
At each step of the psoriasis molecular pathway, different inflammatory cytokines and angiogenic growth factors are involved such as hypoxia inducible factor-1 α (HIF-1 α), vascular endothelial growth factor (VEGF), matrix metalo proteinases (MMPs), basic fibroblast growth factor (bFGF), Angiopoitin-2, interleukin-8 (IL-8), IL-17, and IL-2.
|
28110689 |
2017 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
In future, determination of VEGF gene polymorphisms and thus individual patient VEGF "signatures" may be used as a prognostic factor for psoriasis susceptibility/severity and as a means for optimizing treatment response.
|
16385345 |
2006 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Prolactin and the vascular endothelial growth factor seem to play a key role in psoriasis pathogenesis regarding hyperproliferation of epidermal keratinocytes and dermal vascular ectasia.
|
31384319 |
2019 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thalidomide has been reported being able to inhibit the effects of fibroblast growth factor 2 and vascular endothelial growth factor (VEGF), and inhibit tumour necrosis factor-alpha synthesis, and suppress tumour necrosis factor-induced nuclear factor-kappa B activation in Jurkat cells, resulting in suppression of proliferation inflammation, angiogenesis, and the immune system, which are related to the pathogenesis of psoriasis.
|
28982338 |
2018 |
|
Psoriasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Immunostaining analyses in human psoriasis skin lesions and VEGF-A transgenic mouse skin suggested that the ectodomain shedding of LYVE-1 occurred in lymphatic vessels undergoing chronic inflammation.
|
26966180 |
2016 |